‘Personalised’ treatment results due next year
‘Personalised’ treatment results due next year
After the Phase 2b clinical trial achieved full enrolment with 190 secondary progress multiple sclerosis (SPMS) patients, Texas-based Opexa Therapeutics is now awaiting results for the company’s lead candidate, Tcelna, which are expected in the second half of 2016..... Read More - http://www.ms-uk.org/tcelna
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 1280 Views
-
Last post by NHE
-
- 1 Replies
- 1211 Views
-
Last post by Scott1
-
- 1 Replies
- 1855 Views
-
Last post by frodo
-
- 5 Replies
- 2389 Views
-
Last post by Jaded
-
- 0 Replies
- 4277 Views
-
Last post by NHE
-
- 0 Replies
- 2103 Views
-
Last post by frodo
-
- 0 Replies
- 2356 Views
-
Last post by Cece
-
- 0 Replies
- 2612 Views
-
Last post by NHE
-
- 2 Replies
- 1152 Views
-
Last post by NHE